Evidence map›Paper›PMID 26273462›Full record

ArticleClinical case reports2015

Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussion.

Natalia Myakova, Nadezhda Smirnova, Dmitry Evstratov, Yulia Abugova, Dmitry Balashov, Yulia Diakonova, Dmitry Konovalov, Yulia Skvortsova, Alexey Maschan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Natalia MyakovaFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Nadezhda SmirnovaFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Dmitry EvstratovFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Yulia AbugovaFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Dmitry BalashovFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Yulia DiakonovaFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Dmitry KonovalovFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Yulia SkvortsovaFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.
Alexey MaschanFederal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible relationship between both disorders was discussed.

Indexed as

Brentuximab vedotinchildrenHodgkin lymphomaProteus syndrome

Identifiers

PMID26273462
PMCPMC4527816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.